Research ArticleArticle
OMERACT Endorsement of Measures of Outcome for Studies of Acute Gout
Jasvinder A. Singh, William J. Taylor, Nicola Dalbeth, Lee S. Simon, John Sundy, Rebecca Grainger, Rieke Alten, Lyn March, Vibeke Strand, George Wells, Dinesh Khanna, Fiona McQueen, Naomi Schlesinger, Annelies Boonen, Maarten Boers, Kenneth G. Saag, H. Ralph Schumacher and N. Lawrence Edwards
The Journal of Rheumatology December 2013, jrheum.131246; DOI: https://doi.org/10.3899/jrheum.131246
Jasvinder A. Singh
From Birmingham Veterans Affairs Medical Center and University of Alabama at Birmingham, Birmingham, Alabama, USA; Department of Medicine, University of Otago, Wellington; Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; SDG LLC, Cambridge, Massachusetts,; Duke University School of Medicine, Durham, North Carolina, USA, and Duke-National University of Singapore Graduate Medical School, Singapore; Schlosspark-Klinik Teaching Hospital of the Charité, University Medicine Berlin, Berlin, Germany; University of Sydney Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, Sydney, Australia; Stanford University Division of Immunology and Rheumatology, Portolo Valley, California, USA; University of Ottawa, London, Ontario, Canada; University of Michigan Medical School, Ann Arbor, Michigan, USA; University of Auckland, Department of Molecular Medicine and Pathology, Grafton, Auckland, New Zealand; Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA; Maastricht University Medical Center, Division of Rheumatology, and Caphri Research Institute, University Maastricht; VU University Medical Center, Amsterdam, the Netherlands; University of Pennsylvania and Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania; Department of Rheumatology, University of Florida, Gainsville, Florida, USA. Supported with the resources and the use of facilities at the Birmingham VA Medical Center, Alabama, USA (J. Singh) and University of Otago, New Zealand (W. Taylor). J. Singh has received research grants from Takeda and Savient; and consultant fees from Savient, Takeda, Ardea, Regeneron, Allergan, URL pharmaceuticals and Novartis; and is a member of the executive of OMERACT, which receives arms-length funding from 36 companies; a member of the American College of Rheumatology Guidelines Subcommittee of the Quality of Care Committee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. N. Dalbeth has acted as a consultant for Ardea Biosciences, Metabolex, Novartis, and Takeda; her institution has received funding from Fonterra, and she is a named inventor on a patent related to milk products and gout. L. Simon has served on the Board of Directors for Savient Pharmaceuticals, and as a consultant for Takeda. J. Sundy has received research support from Savient Pharmaceuticals, Regeneron, Ardea Biosciences, Metabolex, Nuon Therapeutics, Pharmos; and consulting funds from Savient Pharmaceuticals, Regeneron, Novartis, Ardea Biosciences, Metabolex, Nuon Therapeutics, BioCryst, and Pharmos. V. Strand has received consultant fees from Metabolex, Novartis, and Savient. D. Khanna has received consultant fees from Ardea, Takeda, Novartis, and Savient; and has served on a Speaker Bureau for Savient. N. Schlesinger has received research grants from Novartis, worked on the Advisory Board for Novartis, Takeda, Savient, Enzyme Rx, URL Pharma; served on the Speaker Bureau for Novartis, Takeda, and Savient; and received consultant fees from Novartis and Takeda. K. Saag has received consultant fees from Ardea, Regeneron, and Takeda and served on the Data Safety Monitoring Board for BioCryst. R. Schumacher has received a grant from Takeda and is a consultant with Regeneron, Novartis, Ardea, Metabolex, Savient, BioCryst, Westward, and Pfizer. N. Edwards has received consultant fees from Takeda Pharmaceutical, Savient Pharmaceutical, Ardea Biosciences, Regeneron Pharmaceuticals, Metabolex Pharmaceuticals, and BioCryst Pharmaceuticals. Views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. J.A. Singh, MBBS, MPH, Associate Professor, Birmingham Veterans Affairs Medical Center and University of Alabama at Birmingham; W.J. Taylor, Associate Professor, PhD, FRACP, Department of Medicine, University of Otago; N. Dalbeth, MD, FRACP, Associate Professor, Faculty of Medical and Health Sciences, University of Auckland; L.S. Simon, MD, SDG LLC; J. Sundy, MD, PhD, Associate Professor, Duke University School of Medicine, and Duke-National University of Singapore Graduate Medical School; R. Grainger, MBChB, PhD, FRACP, Senior Lecturer, Department of Medicine, University of Otago Wellington; R. Alten, MD, Schlosspark-Klinik, Teaching Hospital of the Charité, University Medicine Berlin; L. March, MD, PhD, Professor, University of Sydney Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital; V. Strand, MD, FACP, FACR, Clinical Professor, Adjunct, Stanford University Division of Immunology and Rheumatology; G.A. Wells, MSc, PhD, University of Ottawa; D. Khanna, Associate Professor, MD, MS, University of Michigan Medical School; F. McQueen, Professor of Rheumatology, MBChB, MD, University of Auckland Department of Molecular Medicine and Pathology; N. Schlesinger, Professor of Medicine, Chief, Rutgers-Robert Wood Johnson Medical School; A. Boonen, MD, PhD, Maastricht University Medical Center Division of Rheumatology and Caphri Research Institute, University Maastricht; M. Boers, MD, PhD, VU University Medical Center; K. Saag, Professor, MD, MSc, University of Alabama at Birmingham; H.R. Schumacher Jr., University of Pennsylvania and Philadelphia Veterans Affairs Medical Center; N.L. Edwards, MD, Department of Rheumatology, University of Florida. Address correspondence to J. Singh, University of Alabama, Faculty Office Tower 805B, 510 20th St. S, Birmingham, Alabama 35294, USA; E-mail: Jasvinder.md@gmail.com
William J. Taylor
From Birmingham Veterans Affairs Medical Center and University of Alabama at Birmingham, Birmingham, Alabama, USA; Department of Medicine, University of Otago, Wellington; Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; SDG LLC, Cambridge, Massachusetts,; Duke University School of Medicine, Durham, North Carolina, USA, and Duke-National University of Singapore Graduate Medical School, Singapore; Schlosspark-Klinik Teaching Hospital of the Charité, University Medicine Berlin, Berlin, Germany; University of Sydney Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, Sydney, Australia; Stanford University Division of Immunology and Rheumatology, Portolo Valley, California, USA; University of Ottawa, London, Ontario, Canada; University of Michigan Medical School, Ann Arbor, Michigan, USA; University of Auckland, Department of Molecular Medicine and Pathology, Grafton, Auckland, New Zealand; Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA; Maastricht University Medical Center, Division of Rheumatology, and Caphri Research Institute, University Maastricht; VU University Medical Center, Amsterdam, the Netherlands; University of Pennsylvania and Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania; Department of Rheumatology, University of Florida, Gainsville, Florida, USA. Supported with the resources and the use of facilities at the Birmingham VA Medical Center, Alabama, USA (J. Singh) and University of Otago, New Zealand (W. Taylor). J. Singh has received research grants from Takeda and Savient; and consultant fees from Savient, Takeda, Ardea, Regeneron, Allergan, URL pharmaceuticals and Novartis; and is a member of the executive of OMERACT, which receives arms-length funding from 36 companies; a member of the American College of Rheumatology Guidelines Subcommittee of the Quality of Care Committee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. N. Dalbeth has acted as a consultant for Ardea Biosciences, Metabolex, Novartis, and Takeda; her institution has received funding from Fonterra, and she is a named inventor on a patent related to milk products and gout. L. Simon has served on the Board of Directors for Savient Pharmaceuticals, and as a consultant for Takeda. J. Sundy has received research support from Savient Pharmaceuticals, Regeneron, Ardea Biosciences, Metabolex, Nuon Therapeutics, Pharmos; and consulting funds from Savient Pharmaceuticals, Regeneron, Novartis, Ardea Biosciences, Metabolex, Nuon Therapeutics, BioCryst, and Pharmos. V. Strand has received consultant fees from Metabolex, Novartis, and Savient. D. Khanna has received consultant fees from Ardea, Takeda, Novartis, and Savient; and has served on a Speaker Bureau for Savient. N. Schlesinger has received research grants from Novartis, worked on the Advisory Board for Novartis, Takeda, Savient, Enzyme Rx, URL Pharma; served on the Speaker Bureau for Novartis, Takeda, and Savient; and received consultant fees from Novartis and Takeda. K. Saag has received consultant fees from Ardea, Regeneron, and Takeda and served on the Data Safety Monitoring Board for BioCryst. R. Schumacher has received a grant from Takeda and is a consultant with Regeneron, Novartis, Ardea, Metabolex, Savient, BioCryst, Westward, and Pfizer. N. Edwards has received consultant fees from Takeda Pharmaceutical, Savient Pharmaceutical, Ardea Biosciences, Regeneron Pharmaceuticals, Metabolex Pharmaceuticals, and BioCryst Pharmaceuticals. Views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. J.A. Singh, MBBS, MPH, Associate Professor, Birmingham Veterans Affairs Medical Center and University of Alabama at Birmingham; W.J. Taylor, Associate Professor, PhD, FRACP, Department of Medicine, University of Otago; N. Dalbeth, MD, FRACP, Associate Professor, Faculty of Medical and Health Sciences, University of Auckland; L.S. Simon, MD, SDG LLC; J. Sundy, MD, PhD, Associate Professor, Duke University School of Medicine, and Duke-National University of Singapore Graduate Medical School; R. Grainger, MBChB, PhD, FRACP, Senior Lecturer, Department of Medicine, University of Otago Wellington; R. Alten, MD, Schlosspark-Klinik, Teaching Hospital of the Charité, University Medicine Berlin; L. March, MD, PhD, Professor, University of Sydney Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital; V. Strand, MD, FACP, FACR, Clinical Professor, Adjunct, Stanford University Division of Immunology and Rheumatology; G.A. Wells, MSc, PhD, University of Ottawa; D. Khanna, Associate Professor, MD, MS, University of Michigan Medical School; F. McQueen, Professor of Rheumatology, MBChB, MD, University of Auckland Department of Molecular Medicine and Pathology; N. Schlesinger, Professor of Medicine, Chief, Rutgers-Robert Wood Johnson Medical School; A. Boonen, MD, PhD, Maastricht University Medical Center Division of Rheumatology and Caphri Research Institute, University Maastricht; M. Boers, MD, PhD, VU University Medical Center; K. Saag, Professor, MD, MSc, University of Alabama at Birmingham; H.R. Schumacher Jr., University of Pennsylvania and Philadelphia Veterans Affairs Medical Center; N.L. Edwards, MD, Department of Rheumatology, University of Florida. Address correspondence to J. Singh, University of Alabama, Faculty Office Tower 805B, 510 20th St. S, Birmingham, Alabama 35294, USA; E-mail: Jasvinder.md@gmail.com
Nicola Dalbeth
From Birmingham Veterans Affairs Medical Center and University of Alabama at Birmingham, Birmingham, Alabama, USA; Department of Medicine, University of Otago, Wellington; Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; SDG LLC, Cambridge, Massachusetts,; Duke University School of Medicine, Durham, North Carolina, USA, and Duke-National University of Singapore Graduate Medical School, Singapore; Schlosspark-Klinik Teaching Hospital of the Charité, University Medicine Berlin, Berlin, Germany; University of Sydney Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, Sydney, Australia; Stanford University Division of Immunology and Rheumatology, Portolo Valley, California, USA; University of Ottawa, London, Ontario, Canada; University of Michigan Medical School, Ann Arbor, Michigan, USA; University of Auckland, Department of Molecular Medicine and Pathology, Grafton, Auckland, New Zealand; Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA; Maastricht University Medical Center, Division of Rheumatology, and Caphri Research Institute, University Maastricht; VU University Medical Center, Amsterdam, the Netherlands; University of Pennsylvania and Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania; Department of Rheumatology, University of Florida, Gainsville, Florida, USA. Supported with the resources and the use of facilities at the Birmingham VA Medical Center, Alabama, USA (J. Singh) and University of Otago, New Zealand (W. Taylor). J. Singh has received research grants from Takeda and Savient; and consultant fees from Savient, Takeda, Ardea, Regeneron, Allergan, URL pharmaceuticals and Novartis; and is a member of the executive of OMERACT, which receives arms-length funding from 36 companies; a member of the American College of Rheumatology Guidelines Subcommittee of the Quality of Care Committee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. N. Dalbeth has acted as a consultant for Ardea Biosciences, Metabolex, Novartis, and Takeda; her institution has received funding from Fonterra, and she is a named inventor on a patent related to milk products and gout. L. Simon has served on the Board of Directors for Savient Pharmaceuticals, and as a consultant for Takeda. J. Sundy has received research support from Savient Pharmaceuticals, Regeneron, Ardea Biosciences, Metabolex, Nuon Therapeutics, Pharmos; and consulting funds from Savient Pharmaceuticals, Regeneron, Novartis, Ardea Biosciences, Metabolex, Nuon Therapeutics, BioCryst, and Pharmos. V. Strand has received consultant fees from Metabolex, Novartis, and Savient. D. Khanna has received consultant fees from Ardea, Takeda, Novartis, and Savient; and has served on a Speaker Bureau for Savient. N. Schlesinger has received research grants from Novartis, worked on the Advisory Board for Novartis, Takeda, Savient, Enzyme Rx, URL Pharma; served on the Speaker Bureau for Novartis, Takeda, and Savient; and received consultant fees from Novartis and Takeda. K. Saag has received consultant fees from Ardea, Regeneron, and Takeda and served on the Data Safety Monitoring Board for BioCryst. R. Schumacher has received a grant from Takeda and is a consultant with Regeneron, Novartis, Ardea, Metabolex, Savient, BioCryst, Westward, and Pfizer. N. Edwards has received consultant fees from Takeda Pharmaceutical, Savient Pharmaceutical, Ardea Biosciences, Regeneron Pharmaceuticals, Metabolex Pharmaceuticals, and BioCryst Pharmaceuticals. Views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. J.A. Singh, MBBS, MPH, Associate Professor, Birmingham Veterans Affairs Medical Center and University of Alabama at Birmingham; W.J. Taylor, Associate Professor, PhD, FRACP, Department of Medicine, University of Otago; N. Dalbeth, MD, FRACP, Associate Professor, Faculty of Medical and Health Sciences, University of Auckland; L.S. Simon, MD, SDG LLC; J. Sundy, MD, PhD, Associate Professor, Duke University School of Medicine, and Duke-National University of Singapore Graduate Medical School; R. Grainger, MBChB, PhD, FRACP, Senior Lecturer, Department of Medicine, University of Otago Wellington; R. Alten, MD, Schlosspark-Klinik, Teaching Hospital of the Charité, University Medicine Berlin; L. March, MD, PhD, Professor, University of Sydney Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital; V. Strand, MD, FACP, FACR, Clinical Professor, Adjunct, Stanford University Division of Immunology and Rheumatology; G.A. Wells, MSc, PhD, University of Ottawa; D. Khanna, Associate Professor, MD, MS, University of Michigan Medical School; F. McQueen, Professor of Rheumatology, MBChB, MD, University of Auckland Department of Molecular Medicine and Pathology; N. Schlesinger, Professor of Medicine, Chief, Rutgers-Robert Wood Johnson Medical School; A. Boonen, MD, PhD, Maastricht University Medical Center Division of Rheumatology and Caphri Research Institute, University Maastricht; M. Boers, MD, PhD, VU University Medical Center; K. Saag, Professor, MD, MSc, University of Alabama at Birmingham; H.R. Schumacher Jr., University of Pennsylvania and Philadelphia Veterans Affairs Medical Center; N.L. Edwards, MD, Department of Rheumatology, University of Florida. Address correspondence to J. Singh, University of Alabama, Faculty Office Tower 805B, 510 20th St. S, Birmingham, Alabama 35294, USA; E-mail: Jasvinder.md@gmail.com
Lee S. Simon
From Birmingham Veterans Affairs Medical Center and University of Alabama at Birmingham, Birmingham, Alabama, USA; Department of Medicine, University of Otago, Wellington; Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; SDG LLC, Cambridge, Massachusetts,; Duke University School of Medicine, Durham, North Carolina, USA, and Duke-National University of Singapore Graduate Medical School, Singapore; Schlosspark-Klinik Teaching Hospital of the Charité, University Medicine Berlin, Berlin, Germany; University of Sydney Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, Sydney, Australia; Stanford University Division of Immunology and Rheumatology, Portolo Valley, California, USA; University of Ottawa, London, Ontario, Canada; University of Michigan Medical School, Ann Arbor, Michigan, USA; University of Auckland, Department of Molecular Medicine and Pathology, Grafton, Auckland, New Zealand; Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA; Maastricht University Medical Center, Division of Rheumatology, and Caphri Research Institute, University Maastricht; VU University Medical Center, Amsterdam, the Netherlands; University of Pennsylvania and Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania; Department of Rheumatology, University of Florida, Gainsville, Florida, USA. Supported with the resources and the use of facilities at the Birmingham VA Medical Center, Alabama, USA (J. Singh) and University of Otago, New Zealand (W. Taylor). J. Singh has received research grants from Takeda and Savient; and consultant fees from Savient, Takeda, Ardea, Regeneron, Allergan, URL pharmaceuticals and Novartis; and is a member of the executive of OMERACT, which receives arms-length funding from 36 companies; a member of the American College of Rheumatology Guidelines Subcommittee of the Quality of Care Committee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. N. Dalbeth has acted as a consultant for Ardea Biosciences, Metabolex, Novartis, and Takeda; her institution has received funding from Fonterra, and she is a named inventor on a patent related to milk products and gout. L. Simon has served on the Board of Directors for Savient Pharmaceuticals, and as a consultant for Takeda. J. Sundy has received research support from Savient Pharmaceuticals, Regeneron, Ardea Biosciences, Metabolex, Nuon Therapeutics, Pharmos; and consulting funds from Savient Pharmaceuticals, Regeneron, Novartis, Ardea Biosciences, Metabolex, Nuon Therapeutics, BioCryst, and Pharmos. V. Strand has received consultant fees from Metabolex, Novartis, and Savient. D. Khanna has received consultant fees from Ardea, Takeda, Novartis, and Savient; and has served on a Speaker Bureau for Savient. N. Schlesinger has received research grants from Novartis, worked on the Advisory Board for Novartis, Takeda, Savient, Enzyme Rx, URL Pharma; served on the Speaker Bureau for Novartis, Takeda, and Savient; and received consultant fees from Novartis and Takeda. K. Saag has received consultant fees from Ardea, Regeneron, and Takeda and served on the Data Safety Monitoring Board for BioCryst. R. Schumacher has received a grant from Takeda and is a consultant with Regeneron, Novartis, Ardea, Metabolex, Savient, BioCryst, Westward, and Pfizer. N. Edwards has received consultant fees from Takeda Pharmaceutical, Savient Pharmaceutical, Ardea Biosciences, Regeneron Pharmaceuticals, Metabolex Pharmaceuticals, and BioCryst Pharmaceuticals. Views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. J.A. Singh, MBBS, MPH, Associate Professor, Birmingham Veterans Affairs Medical Center and University of Alabama at Birmingham; W.J. Taylor, Associate Professor, PhD, FRACP, Department of Medicine, University of Otago; N. Dalbeth, MD, FRACP, Associate Professor, Faculty of Medical and Health Sciences, University of Auckland; L.S. Simon, MD, SDG LLC; J. Sundy, MD, PhD, Associate Professor, Duke University School of Medicine, and Duke-National University of Singapore Graduate Medical School; R. Grainger, MBChB, PhD, FRACP, Senior Lecturer, Department of Medicine, University of Otago Wellington; R. Alten, MD, Schlosspark-Klinik, Teaching Hospital of the Charité, University Medicine Berlin; L. March, MD, PhD, Professor, University of Sydney Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital; V. Strand, MD, FACP, FACR, Clinical Professor, Adjunct, Stanford University Division of Immunology and Rheumatology; G.A. Wells, MSc, PhD, University of Ottawa; D. Khanna, Associate Professor, MD, MS, University of Michigan Medical School; F. McQueen, Professor of Rheumatology, MBChB, MD, University of Auckland Department of Molecular Medicine and Pathology; N. Schlesinger, Professor of Medicine, Chief, Rutgers-Robert Wood Johnson Medical School; A. Boonen, MD, PhD, Maastricht University Medical Center Division of Rheumatology and Caphri Research Institute, University Maastricht; M. Boers, MD, PhD, VU University Medical Center; K. Saag, Professor, MD, MSc, University of Alabama at Birmingham; H.R. Schumacher Jr., University of Pennsylvania and Philadelphia Veterans Affairs Medical Center; N.L. Edwards, MD, Department of Rheumatology, University of Florida. Address correspondence to J. Singh, University of Alabama, Faculty Office Tower 805B, 510 20th St. S, Birmingham, Alabama 35294, USA; E-mail: Jasvinder.md@gmail.com
John Sundy
From Birmingham Veterans Affairs Medical Center and University of Alabama at Birmingham, Birmingham, Alabama, USA; Department of Medicine, University of Otago, Wellington; Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; SDG LLC, Cambridge, Massachusetts,; Duke University School of Medicine, Durham, North Carolina, USA, and Duke-National University of Singapore Graduate Medical School, Singapore; Schlosspark-Klinik Teaching Hospital of the Charité, University Medicine Berlin, Berlin, Germany; University of Sydney Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, Sydney, Australia; Stanford University Division of Immunology and Rheumatology, Portolo Valley, California, USA; University of Ottawa, London, Ontario, Canada; University of Michigan Medical School, Ann Arbor, Michigan, USA; University of Auckland, Department of Molecular Medicine and Pathology, Grafton, Auckland, New Zealand; Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA; Maastricht University Medical Center, Division of Rheumatology, and Caphri Research Institute, University Maastricht; VU University Medical Center, Amsterdam, the Netherlands; University of Pennsylvania and Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania; Department of Rheumatology, University of Florida, Gainsville, Florida, USA. Supported with the resources and the use of facilities at the Birmingham VA Medical Center, Alabama, USA (J. Singh) and University of Otago, New Zealand (W. Taylor). J. Singh has received research grants from Takeda and Savient; and consultant fees from Savient, Takeda, Ardea, Regeneron, Allergan, URL pharmaceuticals and Novartis; and is a member of the executive of OMERACT, which receives arms-length funding from 36 companies; a member of the American College of Rheumatology Guidelines Subcommittee of the Quality of Care Committee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. N. Dalbeth has acted as a consultant for Ardea Biosciences, Metabolex, Novartis, and Takeda; her institution has received funding from Fonterra, and she is a named inventor on a patent related to milk products and gout. L. Simon has served on the Board of Directors for Savient Pharmaceuticals, and as a consultant for Takeda. J. Sundy has received research support from Savient Pharmaceuticals, Regeneron, Ardea Biosciences, Metabolex, Nuon Therapeutics, Pharmos; and consulting funds from Savient Pharmaceuticals, Regeneron, Novartis, Ardea Biosciences, Metabolex, Nuon Therapeutics, BioCryst, and Pharmos. V. Strand has received consultant fees from Metabolex, Novartis, and Savient. D. Khanna has received consultant fees from Ardea, Takeda, Novartis, and Savient; and has served on a Speaker Bureau for Savient. N. Schlesinger has received research grants from Novartis, worked on the Advisory Board for Novartis, Takeda, Savient, Enzyme Rx, URL Pharma; served on the Speaker Bureau for Novartis, Takeda, and Savient; and received consultant fees from Novartis and Takeda. K. Saag has received consultant fees from Ardea, Regeneron, and Takeda and served on the Data Safety Monitoring Board for BioCryst. R. Schumacher has received a grant from Takeda and is a consultant with Regeneron, Novartis, Ardea, Metabolex, Savient, BioCryst, Westward, and Pfizer. N. Edwards has received consultant fees from Takeda Pharmaceutical, Savient Pharmaceutical, Ardea Biosciences, Regeneron Pharmaceuticals, Metabolex Pharmaceuticals, and BioCryst Pharmaceuticals. Views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. J.A. Singh, MBBS, MPH, Associate Professor, Birmingham Veterans Affairs Medical Center and University of Alabama at Birmingham; W.J. Taylor, Associate Professor, PhD, FRACP, Department of Medicine, University of Otago; N. Dalbeth, MD, FRACP, Associate Professor, Faculty of Medical and Health Sciences, University of Auckland; L.S. Simon, MD, SDG LLC; J. Sundy, MD, PhD, Associate Professor, Duke University School of Medicine, and Duke-National University of Singapore Graduate Medical School; R. Grainger, MBChB, PhD, FRACP, Senior Lecturer, Department of Medicine, University of Otago Wellington; R. Alten, MD, Schlosspark-Klinik, Teaching Hospital of the Charité, University Medicine Berlin; L. March, MD, PhD, Professor, University of Sydney Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital; V. Strand, MD, FACP, FACR, Clinical Professor, Adjunct, Stanford University Division of Immunology and Rheumatology; G.A. Wells, MSc, PhD, University of Ottawa; D. Khanna, Associate Professor, MD, MS, University of Michigan Medical School; F. McQueen, Professor of Rheumatology, MBChB, MD, University of Auckland Department of Molecular Medicine and Pathology; N. Schlesinger, Professor of Medicine, Chief, Rutgers-Robert Wood Johnson Medical School; A. Boonen, MD, PhD, Maastricht University Medical Center Division of Rheumatology and Caphri Research Institute, University Maastricht; M. Boers, MD, PhD, VU University Medical Center; K. Saag, Professor, MD, MSc, University of Alabama at Birmingham; H.R. Schumacher Jr., University of Pennsylvania and Philadelphia Veterans Affairs Medical Center; N.L. Edwards, MD, Department of Rheumatology, University of Florida. Address correspondence to J. Singh, University of Alabama, Faculty Office Tower 805B, 510 20th St. S, Birmingham, Alabama 35294, USA; E-mail: Jasvinder.md@gmail.com
Rebecca Grainger
From Birmingham Veterans Affairs Medical Center and University of Alabama at Birmingham, Birmingham, Alabama, USA; Department of Medicine, University of Otago, Wellington; Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; SDG LLC, Cambridge, Massachusetts,; Duke University School of Medicine, Durham, North Carolina, USA, and Duke-National University of Singapore Graduate Medical School, Singapore; Schlosspark-Klinik Teaching Hospital of the Charité, University Medicine Berlin, Berlin, Germany; University of Sydney Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, Sydney, Australia; Stanford University Division of Immunology and Rheumatology, Portolo Valley, California, USA; University of Ottawa, London, Ontario, Canada; University of Michigan Medical School, Ann Arbor, Michigan, USA; University of Auckland, Department of Molecular Medicine and Pathology, Grafton, Auckland, New Zealand; Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA; Maastricht University Medical Center, Division of Rheumatology, and Caphri Research Institute, University Maastricht; VU University Medical Center, Amsterdam, the Netherlands; University of Pennsylvania and Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania; Department of Rheumatology, University of Florida, Gainsville, Florida, USA. Supported with the resources and the use of facilities at the Birmingham VA Medical Center, Alabama, USA (J. Singh) and University of Otago, New Zealand (W. Taylor). J. Singh has received research grants from Takeda and Savient; and consultant fees from Savient, Takeda, Ardea, Regeneron, Allergan, URL pharmaceuticals and Novartis; and is a member of the executive of OMERACT, which receives arms-length funding from 36 companies; a member of the American College of Rheumatology Guidelines Subcommittee of the Quality of Care Committee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. N. Dalbeth has acted as a consultant for Ardea Biosciences, Metabolex, Novartis, and Takeda; her institution has received funding from Fonterra, and she is a named inventor on a patent related to milk products and gout. L. Simon has served on the Board of Directors for Savient Pharmaceuticals, and as a consultant for Takeda. J. Sundy has received research support from Savient Pharmaceuticals, Regeneron, Ardea Biosciences, Metabolex, Nuon Therapeutics, Pharmos; and consulting funds from Savient Pharmaceuticals, Regeneron, Novartis, Ardea Biosciences, Metabolex, Nuon Therapeutics, BioCryst, and Pharmos. V. Strand has received consultant fees from Metabolex, Novartis, and Savient. D. Khanna has received consultant fees from Ardea, Takeda, Novartis, and Savient; and has served on a Speaker Bureau for Savient. N. Schlesinger has received research grants from Novartis, worked on the Advisory Board for Novartis, Takeda, Savient, Enzyme Rx, URL Pharma; served on the Speaker Bureau for Novartis, Takeda, and Savient; and received consultant fees from Novartis and Takeda. K. Saag has received consultant fees from Ardea, Regeneron, and Takeda and served on the Data Safety Monitoring Board for BioCryst. R. Schumacher has received a grant from Takeda and is a consultant with Regeneron, Novartis, Ardea, Metabolex, Savient, BioCryst, Westward, and Pfizer. N. Edwards has received consultant fees from Takeda Pharmaceutical, Savient Pharmaceutical, Ardea Biosciences, Regeneron Pharmaceuticals, Metabolex Pharmaceuticals, and BioCryst Pharmaceuticals. Views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. J.A. Singh, MBBS, MPH, Associate Professor, Birmingham Veterans Affairs Medical Center and University of Alabama at Birmingham; W.J. Taylor, Associate Professor, PhD, FRACP, Department of Medicine, University of Otago; N. Dalbeth, MD, FRACP, Associate Professor, Faculty of Medical and Health Sciences, University of Auckland; L.S. Simon, MD, SDG LLC; J. Sundy, MD, PhD, Associate Professor, Duke University School of Medicine, and Duke-National University of Singapore Graduate Medical School; R. Grainger, MBChB, PhD, FRACP, Senior Lecturer, Department of Medicine, University of Otago Wellington; R. Alten, MD, Schlosspark-Klinik, Teaching Hospital of the Charité, University Medicine Berlin; L. March, MD, PhD, Professor, University of Sydney Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital; V. Strand, MD, FACP, FACR, Clinical Professor, Adjunct, Stanford University Division of Immunology and Rheumatology; G.A. Wells, MSc, PhD, University of Ottawa; D. Khanna, Associate Professor, MD, MS, University of Michigan Medical School; F. McQueen, Professor of Rheumatology, MBChB, MD, University of Auckland Department of Molecular Medicine and Pathology; N. Schlesinger, Professor of Medicine, Chief, Rutgers-Robert Wood Johnson Medical School; A. Boonen, MD, PhD, Maastricht University Medical Center Division of Rheumatology and Caphri Research Institute, University Maastricht; M. Boers, MD, PhD, VU University Medical Center; K. Saag, Professor, MD, MSc, University of Alabama at Birmingham; H.R. Schumacher Jr., University of Pennsylvania and Philadelphia Veterans Affairs Medical Center; N.L. Edwards, MD, Department of Rheumatology, University of Florida. Address correspondence to J. Singh, University of Alabama, Faculty Office Tower 805B, 510 20th St. S, Birmingham, Alabama 35294, USA; E-mail: Jasvinder.md@gmail.com
Rieke Alten
From Birmingham Veterans Affairs Medical Center and University of Alabama at Birmingham, Birmingham, Alabama, USA; Department of Medicine, University of Otago, Wellington; Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; SDG LLC, Cambridge, Massachusetts,; Duke University School of Medicine, Durham, North Carolina, USA, and Duke-National University of Singapore Graduate Medical School, Singapore; Schlosspark-Klinik Teaching Hospital of the Charité, University Medicine Berlin, Berlin, Germany; University of Sydney Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, Sydney, Australia; Stanford University Division of Immunology and Rheumatology, Portolo Valley, California, USA; University of Ottawa, London, Ontario, Canada; University of Michigan Medical School, Ann Arbor, Michigan, USA; University of Auckland, Department of Molecular Medicine and Pathology, Grafton, Auckland, New Zealand; Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA; Maastricht University Medical Center, Division of Rheumatology, and Caphri Research Institute, University Maastricht; VU University Medical Center, Amsterdam, the Netherlands; University of Pennsylvania and Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania; Department of Rheumatology, University of Florida, Gainsville, Florida, USA. Supported with the resources and the use of facilities at the Birmingham VA Medical Center, Alabama, USA (J. Singh) and University of Otago, New Zealand (W. Taylor). J. Singh has received research grants from Takeda and Savient; and consultant fees from Savient, Takeda, Ardea, Regeneron, Allergan, URL pharmaceuticals and Novartis; and is a member of the executive of OMERACT, which receives arms-length funding from 36 companies; a member of the American College of Rheumatology Guidelines Subcommittee of the Quality of Care Committee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. N. Dalbeth has acted as a consultant for Ardea Biosciences, Metabolex, Novartis, and Takeda; her institution has received funding from Fonterra, and she is a named inventor on a patent related to milk products and gout. L. Simon has served on the Board of Directors for Savient Pharmaceuticals, and as a consultant for Takeda. J. Sundy has received research support from Savient Pharmaceuticals, Regeneron, Ardea Biosciences, Metabolex, Nuon Therapeutics, Pharmos; and consulting funds from Savient Pharmaceuticals, Regeneron, Novartis, Ardea Biosciences, Metabolex, Nuon Therapeutics, BioCryst, and Pharmos. V. Strand has received consultant fees from Metabolex, Novartis, and Savient. D. Khanna has received consultant fees from Ardea, Takeda, Novartis, and Savient; and has served on a Speaker Bureau for Savient. N. Schlesinger has received research grants from Novartis, worked on the Advisory Board for Novartis, Takeda, Savient, Enzyme Rx, URL Pharma; served on the Speaker Bureau for Novartis, Takeda, and Savient; and received consultant fees from Novartis and Takeda. K. Saag has received consultant fees from Ardea, Regeneron, and Takeda and served on the Data Safety Monitoring Board for BioCryst. R. Schumacher has received a grant from Takeda and is a consultant with Regeneron, Novartis, Ardea, Metabolex, Savient, BioCryst, Westward, and Pfizer. N. Edwards has received consultant fees from Takeda Pharmaceutical, Savient Pharmaceutical, Ardea Biosciences, Regeneron Pharmaceuticals, Metabolex Pharmaceuticals, and BioCryst Pharmaceuticals. Views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. J.A. Singh, MBBS, MPH, Associate Professor, Birmingham Veterans Affairs Medical Center and University of Alabama at Birmingham; W.J. Taylor, Associate Professor, PhD, FRACP, Department of Medicine, University of Otago; N. Dalbeth, MD, FRACP, Associate Professor, Faculty of Medical and Health Sciences, University of Auckland; L.S. Simon, MD, SDG LLC; J. Sundy, MD, PhD, Associate Professor, Duke University School of Medicine, and Duke-National University of Singapore Graduate Medical School; R. Grainger, MBChB, PhD, FRACP, Senior Lecturer, Department of Medicine, University of Otago Wellington; R. Alten, MD, Schlosspark-Klinik, Teaching Hospital of the Charité, University Medicine Berlin; L. March, MD, PhD, Professor, University of Sydney Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital; V. Strand, MD, FACP, FACR, Clinical Professor, Adjunct, Stanford University Division of Immunology and Rheumatology; G.A. Wells, MSc, PhD, University of Ottawa; D. Khanna, Associate Professor, MD, MS, University of Michigan Medical School; F. McQueen, Professor of Rheumatology, MBChB, MD, University of Auckland Department of Molecular Medicine and Pathology; N. Schlesinger, Professor of Medicine, Chief, Rutgers-Robert Wood Johnson Medical School; A. Boonen, MD, PhD, Maastricht University Medical Center Division of Rheumatology and Caphri Research Institute, University Maastricht; M. Boers, MD, PhD, VU University Medical Center; K. Saag, Professor, MD, MSc, University of Alabama at Birmingham; H.R. Schumacher Jr., University of Pennsylvania and Philadelphia Veterans Affairs Medical Center; N.L. Edwards, MD, Department of Rheumatology, University of Florida. Address correspondence to J. Singh, University of Alabama, Faculty Office Tower 805B, 510 20th St. S, Birmingham, Alabama 35294, USA; E-mail: Jasvinder.md@gmail.com
Lyn March
From Birmingham Veterans Affairs Medical Center and University of Alabama at Birmingham, Birmingham, Alabama, USA; Department of Medicine, University of Otago, Wellington; Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; SDG LLC, Cambridge, Massachusetts,; Duke University School of Medicine, Durham, North Carolina, USA, and Duke-National University of Singapore Graduate Medical School, Singapore; Schlosspark-Klinik Teaching Hospital of the Charité, University Medicine Berlin, Berlin, Germany; University of Sydney Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, Sydney, Australia; Stanford University Division of Immunology and Rheumatology, Portolo Valley, California, USA; University of Ottawa, London, Ontario, Canada; University of Michigan Medical School, Ann Arbor, Michigan, USA; University of Auckland, Department of Molecular Medicine and Pathology, Grafton, Auckland, New Zealand; Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA; Maastricht University Medical Center, Division of Rheumatology, and Caphri Research Institute, University Maastricht; VU University Medical Center, Amsterdam, the Netherlands; University of Pennsylvania and Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania; Department of Rheumatology, University of Florida, Gainsville, Florida, USA. Supported with the resources and the use of facilities at the Birmingham VA Medical Center, Alabama, USA (J. Singh) and University of Otago, New Zealand (W. Taylor). J. Singh has received research grants from Takeda and Savient; and consultant fees from Savient, Takeda, Ardea, Regeneron, Allergan, URL pharmaceuticals and Novartis; and is a member of the executive of OMERACT, which receives arms-length funding from 36 companies; a member of the American College of Rheumatology Guidelines Subcommittee of the Quality of Care Committee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. N. Dalbeth has acted as a consultant for Ardea Biosciences, Metabolex, Novartis, and Takeda; her institution has received funding from Fonterra, and she is a named inventor on a patent related to milk products and gout. L. Simon has served on the Board of Directors for Savient Pharmaceuticals, and as a consultant for Takeda. J. Sundy has received research support from Savient Pharmaceuticals, Regeneron, Ardea Biosciences, Metabolex, Nuon Therapeutics, Pharmos; and consulting funds from Savient Pharmaceuticals, Regeneron, Novartis, Ardea Biosciences, Metabolex, Nuon Therapeutics, BioCryst, and Pharmos. V. Strand has received consultant fees from Metabolex, Novartis, and Savient. D. Khanna has received consultant fees from Ardea, Takeda, Novartis, and Savient; and has served on a Speaker Bureau for Savient. N. Schlesinger has received research grants from Novartis, worked on the Advisory Board for Novartis, Takeda, Savient, Enzyme Rx, URL Pharma; served on the Speaker Bureau for Novartis, Takeda, and Savient; and received consultant fees from Novartis and Takeda. K. Saag has received consultant fees from Ardea, Regeneron, and Takeda and served on the Data Safety Monitoring Board for BioCryst. R. Schumacher has received a grant from Takeda and is a consultant with Regeneron, Novartis, Ardea, Metabolex, Savient, BioCryst, Westward, and Pfizer. N. Edwards has received consultant fees from Takeda Pharmaceutical, Savient Pharmaceutical, Ardea Biosciences, Regeneron Pharmaceuticals, Metabolex Pharmaceuticals, and BioCryst Pharmaceuticals. Views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. J.A. Singh, MBBS, MPH, Associate Professor, Birmingham Veterans Affairs Medical Center and University of Alabama at Birmingham; W.J. Taylor, Associate Professor, PhD, FRACP, Department of Medicine, University of Otago; N. Dalbeth, MD, FRACP, Associate Professor, Faculty of Medical and Health Sciences, University of Auckland; L.S. Simon, MD, SDG LLC; J. Sundy, MD, PhD, Associate Professor, Duke University School of Medicine, and Duke-National University of Singapore Graduate Medical School; R. Grainger, MBChB, PhD, FRACP, Senior Lecturer, Department of Medicine, University of Otago Wellington; R. Alten, MD, Schlosspark-Klinik, Teaching Hospital of the Charité, University Medicine Berlin; L. March, MD, PhD, Professor, University of Sydney Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital; V. Strand, MD, FACP, FACR, Clinical Professor, Adjunct, Stanford University Division of Immunology and Rheumatology; G.A. Wells, MSc, PhD, University of Ottawa; D. Khanna, Associate Professor, MD, MS, University of Michigan Medical School; F. McQueen, Professor of Rheumatology, MBChB, MD, University of Auckland Department of Molecular Medicine and Pathology; N. Schlesinger, Professor of Medicine, Chief, Rutgers-Robert Wood Johnson Medical School; A. Boonen, MD, PhD, Maastricht University Medical Center Division of Rheumatology and Caphri Research Institute, University Maastricht; M. Boers, MD, PhD, VU University Medical Center; K. Saag, Professor, MD, MSc, University of Alabama at Birmingham; H.R. Schumacher Jr., University of Pennsylvania and Philadelphia Veterans Affairs Medical Center; N.L. Edwards, MD, Department of Rheumatology, University of Florida. Address correspondence to J. Singh, University of Alabama, Faculty Office Tower 805B, 510 20th St. S, Birmingham, Alabama 35294, USA; E-mail: Jasvinder.md@gmail.com
Vibeke Strand
From Birmingham Veterans Affairs Medical Center and University of Alabama at Birmingham, Birmingham, Alabama, USA; Department of Medicine, University of Otago, Wellington; Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; SDG LLC, Cambridge, Massachusetts,; Duke University School of Medicine, Durham, North Carolina, USA, and Duke-National University of Singapore Graduate Medical School, Singapore; Schlosspark-Klinik Teaching Hospital of the Charité, University Medicine Berlin, Berlin, Germany; University of Sydney Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, Sydney, Australia; Stanford University Division of Immunology and Rheumatology, Portolo Valley, California, USA; University of Ottawa, London, Ontario, Canada; University of Michigan Medical School, Ann Arbor, Michigan, USA; University of Auckland, Department of Molecular Medicine and Pathology, Grafton, Auckland, New Zealand; Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA; Maastricht University Medical Center, Division of Rheumatology, and Caphri Research Institute, University Maastricht; VU University Medical Center, Amsterdam, the Netherlands; University of Pennsylvania and Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania; Department of Rheumatology, University of Florida, Gainsville, Florida, USA. Supported with the resources and the use of facilities at the Birmingham VA Medical Center, Alabama, USA (J. Singh) and University of Otago, New Zealand (W. Taylor). J. Singh has received research grants from Takeda and Savient; and consultant fees from Savient, Takeda, Ardea, Regeneron, Allergan, URL pharmaceuticals and Novartis; and is a member of the executive of OMERACT, which receives arms-length funding from 36 companies; a member of the American College of Rheumatology Guidelines Subcommittee of the Quality of Care Committee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. N. Dalbeth has acted as a consultant for Ardea Biosciences, Metabolex, Novartis, and Takeda; her institution has received funding from Fonterra, and she is a named inventor on a patent related to milk products and gout. L. Simon has served on the Board of Directors for Savient Pharmaceuticals, and as a consultant for Takeda. J. Sundy has received research support from Savient Pharmaceuticals, Regeneron, Ardea Biosciences, Metabolex, Nuon Therapeutics, Pharmos; and consulting funds from Savient Pharmaceuticals, Regeneron, Novartis, Ardea Biosciences, Metabolex, Nuon Therapeutics, BioCryst, and Pharmos. V. Strand has received consultant fees from Metabolex, Novartis, and Savient. D. Khanna has received consultant fees from Ardea, Takeda, Novartis, and Savient; and has served on a Speaker Bureau for Savient. N. Schlesinger has received research grants from Novartis, worked on the Advisory Board for Novartis, Takeda, Savient, Enzyme Rx, URL Pharma; served on the Speaker Bureau for Novartis, Takeda, and Savient; and received consultant fees from Novartis and Takeda. K. Saag has received consultant fees from Ardea, Regeneron, and Takeda and served on the Data Safety Monitoring Board for BioCryst. R. Schumacher has received a grant from Takeda and is a consultant with Regeneron, Novartis, Ardea, Metabolex, Savient, BioCryst, Westward, and Pfizer. N. Edwards has received consultant fees from Takeda Pharmaceutical, Savient Pharmaceutical, Ardea Biosciences, Regeneron Pharmaceuticals, Metabolex Pharmaceuticals, and BioCryst Pharmaceuticals. Views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. J.A. Singh, MBBS, MPH, Associate Professor, Birmingham Veterans Affairs Medical Center and University of Alabama at Birmingham; W.J. Taylor, Associate Professor, PhD, FRACP, Department of Medicine, University of Otago; N. Dalbeth, MD, FRACP, Associate Professor, Faculty of Medical and Health Sciences, University of Auckland; L.S. Simon, MD, SDG LLC; J. Sundy, MD, PhD, Associate Professor, Duke University School of Medicine, and Duke-National University of Singapore Graduate Medical School; R. Grainger, MBChB, PhD, FRACP, Senior Lecturer, Department of Medicine, University of Otago Wellington; R. Alten, MD, Schlosspark-Klinik, Teaching Hospital of the Charité, University Medicine Berlin; L. March, MD, PhD, Professor, University of Sydney Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital; V. Strand, MD, FACP, FACR, Clinical Professor, Adjunct, Stanford University Division of Immunology and Rheumatology; G.A. Wells, MSc, PhD, University of Ottawa; D. Khanna, Associate Professor, MD, MS, University of Michigan Medical School; F. McQueen, Professor of Rheumatology, MBChB, MD, University of Auckland Department of Molecular Medicine and Pathology; N. Schlesinger, Professor of Medicine, Chief, Rutgers-Robert Wood Johnson Medical School; A. Boonen, MD, PhD, Maastricht University Medical Center Division of Rheumatology and Caphri Research Institute, University Maastricht; M. Boers, MD, PhD, VU University Medical Center; K. Saag, Professor, MD, MSc, University of Alabama at Birmingham; H.R. Schumacher Jr., University of Pennsylvania and Philadelphia Veterans Affairs Medical Center; N.L. Edwards, MD, Department of Rheumatology, University of Florida. Address correspondence to J. Singh, University of Alabama, Faculty Office Tower 805B, 510 20th St. S, Birmingham, Alabama 35294, USA; E-mail: Jasvinder.md@gmail.com
George Wells
From Birmingham Veterans Affairs Medical Center and University of Alabama at Birmingham, Birmingham, Alabama, USA; Department of Medicine, University of Otago, Wellington; Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; SDG LLC, Cambridge, Massachusetts,; Duke University School of Medicine, Durham, North Carolina, USA, and Duke-National University of Singapore Graduate Medical School, Singapore; Schlosspark-Klinik Teaching Hospital of the Charité, University Medicine Berlin, Berlin, Germany; University of Sydney Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, Sydney, Australia; Stanford University Division of Immunology and Rheumatology, Portolo Valley, California, USA; University of Ottawa, London, Ontario, Canada; University of Michigan Medical School, Ann Arbor, Michigan, USA; University of Auckland, Department of Molecular Medicine and Pathology, Grafton, Auckland, New Zealand; Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA; Maastricht University Medical Center, Division of Rheumatology, and Caphri Research Institute, University Maastricht; VU University Medical Center, Amsterdam, the Netherlands; University of Pennsylvania and Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania; Department of Rheumatology, University of Florida, Gainsville, Florida, USA. Supported with the resources and the use of facilities at the Birmingham VA Medical Center, Alabama, USA (J. Singh) and University of Otago, New Zealand (W. Taylor). J. Singh has received research grants from Takeda and Savient; and consultant fees from Savient, Takeda, Ardea, Regeneron, Allergan, URL pharmaceuticals and Novartis; and is a member of the executive of OMERACT, which receives arms-length funding from 36 companies; a member of the American College of Rheumatology Guidelines Subcommittee of the Quality of Care Committee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. N. Dalbeth has acted as a consultant for Ardea Biosciences, Metabolex, Novartis, and Takeda; her institution has received funding from Fonterra, and she is a named inventor on a patent related to milk products and gout. L. Simon has served on the Board of Directors for Savient Pharmaceuticals, and as a consultant for Takeda. J. Sundy has received research support from Savient Pharmaceuticals, Regeneron, Ardea Biosciences, Metabolex, Nuon Therapeutics, Pharmos; and consulting funds from Savient Pharmaceuticals, Regeneron, Novartis, Ardea Biosciences, Metabolex, Nuon Therapeutics, BioCryst, and Pharmos. V. Strand has received consultant fees from Metabolex, Novartis, and Savient. D. Khanna has received consultant fees from Ardea, Takeda, Novartis, and Savient; and has served on a Speaker Bureau for Savient. N. Schlesinger has received research grants from Novartis, worked on the Advisory Board for Novartis, Takeda, Savient, Enzyme Rx, URL Pharma; served on the Speaker Bureau for Novartis, Takeda, and Savient; and received consultant fees from Novartis and Takeda. K. Saag has received consultant fees from Ardea, Regeneron, and Takeda and served on the Data Safety Monitoring Board for BioCryst. R. Schumacher has received a grant from Takeda and is a consultant with Regeneron, Novartis, Ardea, Metabolex, Savient, BioCryst, Westward, and Pfizer. N. Edwards has received consultant fees from Takeda Pharmaceutical, Savient Pharmaceutical, Ardea Biosciences, Regeneron Pharmaceuticals, Metabolex Pharmaceuticals, and BioCryst Pharmaceuticals. Views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. J.A. Singh, MBBS, MPH, Associate Professor, Birmingham Veterans Affairs Medical Center and University of Alabama at Birmingham; W.J. Taylor, Associate Professor, PhD, FRACP, Department of Medicine, University of Otago; N. Dalbeth, MD, FRACP, Associate Professor, Faculty of Medical and Health Sciences, University of Auckland; L.S. Simon, MD, SDG LLC; J. Sundy, MD, PhD, Associate Professor, Duke University School of Medicine, and Duke-National University of Singapore Graduate Medical School; R. Grainger, MBChB, PhD, FRACP, Senior Lecturer, Department of Medicine, University of Otago Wellington; R. Alten, MD, Schlosspark-Klinik, Teaching Hospital of the Charité, University Medicine Berlin; L. March, MD, PhD, Professor, University of Sydney Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital; V. Strand, MD, FACP, FACR, Clinical Professor, Adjunct, Stanford University Division of Immunology and Rheumatology; G.A. Wells, MSc, PhD, University of Ottawa; D. Khanna, Associate Professor, MD, MS, University of Michigan Medical School; F. McQueen, Professor of Rheumatology, MBChB, MD, University of Auckland Department of Molecular Medicine and Pathology; N. Schlesinger, Professor of Medicine, Chief, Rutgers-Robert Wood Johnson Medical School; A. Boonen, MD, PhD, Maastricht University Medical Center Division of Rheumatology and Caphri Research Institute, University Maastricht; M. Boers, MD, PhD, VU University Medical Center; K. Saag, Professor, MD, MSc, University of Alabama at Birmingham; H.R. Schumacher Jr., University of Pennsylvania and Philadelphia Veterans Affairs Medical Center; N.L. Edwards, MD, Department of Rheumatology, University of Florida. Address correspondence to J. Singh, University of Alabama, Faculty Office Tower 805B, 510 20th St. S, Birmingham, Alabama 35294, USA; E-mail: Jasvinder.md@gmail.com
Dinesh Khanna
From Birmingham Veterans Affairs Medical Center and University of Alabama at Birmingham, Birmingham, Alabama, USA; Department of Medicine, University of Otago, Wellington; Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; SDG LLC, Cambridge, Massachusetts,; Duke University School of Medicine, Durham, North Carolina, USA, and Duke-National University of Singapore Graduate Medical School, Singapore; Schlosspark-Klinik Teaching Hospital of the Charité, University Medicine Berlin, Berlin, Germany; University of Sydney Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, Sydney, Australia; Stanford University Division of Immunology and Rheumatology, Portolo Valley, California, USA; University of Ottawa, London, Ontario, Canada; University of Michigan Medical School, Ann Arbor, Michigan, USA; University of Auckland, Department of Molecular Medicine and Pathology, Grafton, Auckland, New Zealand; Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA; Maastricht University Medical Center, Division of Rheumatology, and Caphri Research Institute, University Maastricht; VU University Medical Center, Amsterdam, the Netherlands; University of Pennsylvania and Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania; Department of Rheumatology, University of Florida, Gainsville, Florida, USA. Supported with the resources and the use of facilities at the Birmingham VA Medical Center, Alabama, USA (J. Singh) and University of Otago, New Zealand (W. Taylor). J. Singh has received research grants from Takeda and Savient; and consultant fees from Savient, Takeda, Ardea, Regeneron, Allergan, URL pharmaceuticals and Novartis; and is a member of the executive of OMERACT, which receives arms-length funding from 36 companies; a member of the American College of Rheumatology Guidelines Subcommittee of the Quality of Care Committee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. N. Dalbeth has acted as a consultant for Ardea Biosciences, Metabolex, Novartis, and Takeda; her institution has received funding from Fonterra, and she is a named inventor on a patent related to milk products and gout. L. Simon has served on the Board of Directors for Savient Pharmaceuticals, and as a consultant for Takeda. J. Sundy has received research support from Savient Pharmaceuticals, Regeneron, Ardea Biosciences, Metabolex, Nuon Therapeutics, Pharmos; and consulting funds from Savient Pharmaceuticals, Regeneron, Novartis, Ardea Biosciences, Metabolex, Nuon Therapeutics, BioCryst, and Pharmos. V. Strand has received consultant fees from Metabolex, Novartis, and Savient. D. Khanna has received consultant fees from Ardea, Takeda, Novartis, and Savient; and has served on a Speaker Bureau for Savient. N. Schlesinger has received research grants from Novartis, worked on the Advisory Board for Novartis, Takeda, Savient, Enzyme Rx, URL Pharma; served on the Speaker Bureau for Novartis, Takeda, and Savient; and received consultant fees from Novartis and Takeda. K. Saag has received consultant fees from Ardea, Regeneron, and Takeda and served on the Data Safety Monitoring Board for BioCryst. R. Schumacher has received a grant from Takeda and is a consultant with Regeneron, Novartis, Ardea, Metabolex, Savient, BioCryst, Westward, and Pfizer. N. Edwards has received consultant fees from Takeda Pharmaceutical, Savient Pharmaceutical, Ardea Biosciences, Regeneron Pharmaceuticals, Metabolex Pharmaceuticals, and BioCryst Pharmaceuticals. Views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. J.A. Singh, MBBS, MPH, Associate Professor, Birmingham Veterans Affairs Medical Center and University of Alabama at Birmingham; W.J. Taylor, Associate Professor, PhD, FRACP, Department of Medicine, University of Otago; N. Dalbeth, MD, FRACP, Associate Professor, Faculty of Medical and Health Sciences, University of Auckland; L.S. Simon, MD, SDG LLC; J. Sundy, MD, PhD, Associate Professor, Duke University School of Medicine, and Duke-National University of Singapore Graduate Medical School; R. Grainger, MBChB, PhD, FRACP, Senior Lecturer, Department of Medicine, University of Otago Wellington; R. Alten, MD, Schlosspark-Klinik, Teaching Hospital of the Charité, University Medicine Berlin; L. March, MD, PhD, Professor, University of Sydney Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital; V. Strand, MD, FACP, FACR, Clinical Professor, Adjunct, Stanford University Division of Immunology and Rheumatology; G.A. Wells, MSc, PhD, University of Ottawa; D. Khanna, Associate Professor, MD, MS, University of Michigan Medical School; F. McQueen, Professor of Rheumatology, MBChB, MD, University of Auckland Department of Molecular Medicine and Pathology; N. Schlesinger, Professor of Medicine, Chief, Rutgers-Robert Wood Johnson Medical School; A. Boonen, MD, PhD, Maastricht University Medical Center Division of Rheumatology and Caphri Research Institute, University Maastricht; M. Boers, MD, PhD, VU University Medical Center; K. Saag, Professor, MD, MSc, University of Alabama at Birmingham; H.R. Schumacher Jr., University of Pennsylvania and Philadelphia Veterans Affairs Medical Center; N.L. Edwards, MD, Department of Rheumatology, University of Florida. Address correspondence to J. Singh, University of Alabama, Faculty Office Tower 805B, 510 20th St. S, Birmingham, Alabama 35294, USA; E-mail: Jasvinder.md@gmail.com
Fiona McQueen
From Birmingham Veterans Affairs Medical Center and University of Alabama at Birmingham, Birmingham, Alabama, USA; Department of Medicine, University of Otago, Wellington; Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; SDG LLC, Cambridge, Massachusetts,; Duke University School of Medicine, Durham, North Carolina, USA, and Duke-National University of Singapore Graduate Medical School, Singapore; Schlosspark-Klinik Teaching Hospital of the Charité, University Medicine Berlin, Berlin, Germany; University of Sydney Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, Sydney, Australia; Stanford University Division of Immunology and Rheumatology, Portolo Valley, California, USA; University of Ottawa, London, Ontario, Canada; University of Michigan Medical School, Ann Arbor, Michigan, USA; University of Auckland, Department of Molecular Medicine and Pathology, Grafton, Auckland, New Zealand; Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA; Maastricht University Medical Center, Division of Rheumatology, and Caphri Research Institute, University Maastricht; VU University Medical Center, Amsterdam, the Netherlands; University of Pennsylvania and Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania; Department of Rheumatology, University of Florida, Gainsville, Florida, USA. Supported with the resources and the use of facilities at the Birmingham VA Medical Center, Alabama, USA (J. Singh) and University of Otago, New Zealand (W. Taylor). J. Singh has received research grants from Takeda and Savient; and consultant fees from Savient, Takeda, Ardea, Regeneron, Allergan, URL pharmaceuticals and Novartis; and is a member of the executive of OMERACT, which receives arms-length funding from 36 companies; a member of the American College of Rheumatology Guidelines Subcommittee of the Quality of Care Committee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. N. Dalbeth has acted as a consultant for Ardea Biosciences, Metabolex, Novartis, and Takeda; her institution has received funding from Fonterra, and she is a named inventor on a patent related to milk products and gout. L. Simon has served on the Board of Directors for Savient Pharmaceuticals, and as a consultant for Takeda. J. Sundy has received research support from Savient Pharmaceuticals, Regeneron, Ardea Biosciences, Metabolex, Nuon Therapeutics, Pharmos; and consulting funds from Savient Pharmaceuticals, Regeneron, Novartis, Ardea Biosciences, Metabolex, Nuon Therapeutics, BioCryst, and Pharmos. V. Strand has received consultant fees from Metabolex, Novartis, and Savient. D. Khanna has received consultant fees from Ardea, Takeda, Novartis, and Savient; and has served on a Speaker Bureau for Savient. N. Schlesinger has received research grants from Novartis, worked on the Advisory Board for Novartis, Takeda, Savient, Enzyme Rx, URL Pharma; served on the Speaker Bureau for Novartis, Takeda, and Savient; and received consultant fees from Novartis and Takeda. K. Saag has received consultant fees from Ardea, Regeneron, and Takeda and served on the Data Safety Monitoring Board for BioCryst. R. Schumacher has received a grant from Takeda and is a consultant with Regeneron, Novartis, Ardea, Metabolex, Savient, BioCryst, Westward, and Pfizer. N. Edwards has received consultant fees from Takeda Pharmaceutical, Savient Pharmaceutical, Ardea Biosciences, Regeneron Pharmaceuticals, Metabolex Pharmaceuticals, and BioCryst Pharmaceuticals. Views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. J.A. Singh, MBBS, MPH, Associate Professor, Birmingham Veterans Affairs Medical Center and University of Alabama at Birmingham; W.J. Taylor, Associate Professor, PhD, FRACP, Department of Medicine, University of Otago; N. Dalbeth, MD, FRACP, Associate Professor, Faculty of Medical and Health Sciences, University of Auckland; L.S. Simon, MD, SDG LLC; J. Sundy, MD, PhD, Associate Professor, Duke University School of Medicine, and Duke-National University of Singapore Graduate Medical School; R. Grainger, MBChB, PhD, FRACP, Senior Lecturer, Department of Medicine, University of Otago Wellington; R. Alten, MD, Schlosspark-Klinik, Teaching Hospital of the Charité, University Medicine Berlin; L. March, MD, PhD, Professor, University of Sydney Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital; V. Strand, MD, FACP, FACR, Clinical Professor, Adjunct, Stanford University Division of Immunology and Rheumatology; G.A. Wells, MSc, PhD, University of Ottawa; D. Khanna, Associate Professor, MD, MS, University of Michigan Medical School; F. McQueen, Professor of Rheumatology, MBChB, MD, University of Auckland Department of Molecular Medicine and Pathology; N. Schlesinger, Professor of Medicine, Chief, Rutgers-Robert Wood Johnson Medical School; A. Boonen, MD, PhD, Maastricht University Medical Center Division of Rheumatology and Caphri Research Institute, University Maastricht; M. Boers, MD, PhD, VU University Medical Center; K. Saag, Professor, MD, MSc, University of Alabama at Birmingham; H.R. Schumacher Jr., University of Pennsylvania and Philadelphia Veterans Affairs Medical Center; N.L. Edwards, MD, Department of Rheumatology, University of Florida. Address correspondence to J. Singh, University of Alabama, Faculty Office Tower 805B, 510 20th St. S, Birmingham, Alabama 35294, USA; E-mail: Jasvinder.md@gmail.com
Naomi Schlesinger
From Birmingham Veterans Affairs Medical Center and University of Alabama at Birmingham, Birmingham, Alabama, USA; Department of Medicine, University of Otago, Wellington; Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; SDG LLC, Cambridge, Massachusetts,; Duke University School of Medicine, Durham, North Carolina, USA, and Duke-National University of Singapore Graduate Medical School, Singapore; Schlosspark-Klinik Teaching Hospital of the Charité, University Medicine Berlin, Berlin, Germany; University of Sydney Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, Sydney, Australia; Stanford University Division of Immunology and Rheumatology, Portolo Valley, California, USA; University of Ottawa, London, Ontario, Canada; University of Michigan Medical School, Ann Arbor, Michigan, USA; University of Auckland, Department of Molecular Medicine and Pathology, Grafton, Auckland, New Zealand; Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA; Maastricht University Medical Center, Division of Rheumatology, and Caphri Research Institute, University Maastricht; VU University Medical Center, Amsterdam, the Netherlands; University of Pennsylvania and Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania; Department of Rheumatology, University of Florida, Gainsville, Florida, USA. Supported with the resources and the use of facilities at the Birmingham VA Medical Center, Alabama, USA (J. Singh) and University of Otago, New Zealand (W. Taylor). J. Singh has received research grants from Takeda and Savient; and consultant fees from Savient, Takeda, Ardea, Regeneron, Allergan, URL pharmaceuticals and Novartis; and is a member of the executive of OMERACT, which receives arms-length funding from 36 companies; a member of the American College of Rheumatology Guidelines Subcommittee of the Quality of Care Committee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. N. Dalbeth has acted as a consultant for Ardea Biosciences, Metabolex, Novartis, and Takeda; her institution has received funding from Fonterra, and she is a named inventor on a patent related to milk products and gout. L. Simon has served on the Board of Directors for Savient Pharmaceuticals, and as a consultant for Takeda. J. Sundy has received research support from Savient Pharmaceuticals, Regeneron, Ardea Biosciences, Metabolex, Nuon Therapeutics, Pharmos; and consulting funds from Savient Pharmaceuticals, Regeneron, Novartis, Ardea Biosciences, Metabolex, Nuon Therapeutics, BioCryst, and Pharmos. V. Strand has received consultant fees from Metabolex, Novartis, and Savient. D. Khanna has received consultant fees from Ardea, Takeda, Novartis, and Savient; and has served on a Speaker Bureau for Savient. N. Schlesinger has received research grants from Novartis, worked on the Advisory Board for Novartis, Takeda, Savient, Enzyme Rx, URL Pharma; served on the Speaker Bureau for Novartis, Takeda, and Savient; and received consultant fees from Novartis and Takeda. K. Saag has received consultant fees from Ardea, Regeneron, and Takeda and served on the Data Safety Monitoring Board for BioCryst. R. Schumacher has received a grant from Takeda and is a consultant with Regeneron, Novartis, Ardea, Metabolex, Savient, BioCryst, Westward, and Pfizer. N. Edwards has received consultant fees from Takeda Pharmaceutical, Savient Pharmaceutical, Ardea Biosciences, Regeneron Pharmaceuticals, Metabolex Pharmaceuticals, and BioCryst Pharmaceuticals. Views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. J.A. Singh, MBBS, MPH, Associate Professor, Birmingham Veterans Affairs Medical Center and University of Alabama at Birmingham; W.J. Taylor, Associate Professor, PhD, FRACP, Department of Medicine, University of Otago; N. Dalbeth, MD, FRACP, Associate Professor, Faculty of Medical and Health Sciences, University of Auckland; L.S. Simon, MD, SDG LLC; J. Sundy, MD, PhD, Associate Professor, Duke University School of Medicine, and Duke-National University of Singapore Graduate Medical School; R. Grainger, MBChB, PhD, FRACP, Senior Lecturer, Department of Medicine, University of Otago Wellington; R. Alten, MD, Schlosspark-Klinik, Teaching Hospital of the Charité, University Medicine Berlin; L. March, MD, PhD, Professor, University of Sydney Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital; V. Strand, MD, FACP, FACR, Clinical Professor, Adjunct, Stanford University Division of Immunology and Rheumatology; G.A. Wells, MSc, PhD, University of Ottawa; D. Khanna, Associate Professor, MD, MS, University of Michigan Medical School; F. McQueen, Professor of Rheumatology, MBChB, MD, University of Auckland Department of Molecular Medicine and Pathology; N. Schlesinger, Professor of Medicine, Chief, Rutgers-Robert Wood Johnson Medical School; A. Boonen, MD, PhD, Maastricht University Medical Center Division of Rheumatology and Caphri Research Institute, University Maastricht; M. Boers, MD, PhD, VU University Medical Center; K. Saag, Professor, MD, MSc, University of Alabama at Birmingham; H.R. Schumacher Jr., University of Pennsylvania and Philadelphia Veterans Affairs Medical Center; N.L. Edwards, MD, Department of Rheumatology, University of Florida. Address correspondence to J. Singh, University of Alabama, Faculty Office Tower 805B, 510 20th St. S, Birmingham, Alabama 35294, USA; E-mail: Jasvinder.md@gmail.com
Annelies Boonen
From Birmingham Veterans Affairs Medical Center and University of Alabama at Birmingham, Birmingham, Alabama, USA; Department of Medicine, University of Otago, Wellington; Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; SDG LLC, Cambridge, Massachusetts,; Duke University School of Medicine, Durham, North Carolina, USA, and Duke-National University of Singapore Graduate Medical School, Singapore; Schlosspark-Klinik Teaching Hospital of the Charité, University Medicine Berlin, Berlin, Germany; University of Sydney Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, Sydney, Australia; Stanford University Division of Immunology and Rheumatology, Portolo Valley, California, USA; University of Ottawa, London, Ontario, Canada; University of Michigan Medical School, Ann Arbor, Michigan, USA; University of Auckland, Department of Molecular Medicine and Pathology, Grafton, Auckland, New Zealand; Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA; Maastricht University Medical Center, Division of Rheumatology, and Caphri Research Institute, University Maastricht; VU University Medical Center, Amsterdam, the Netherlands; University of Pennsylvania and Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania; Department of Rheumatology, University of Florida, Gainsville, Florida, USA. Supported with the resources and the use of facilities at the Birmingham VA Medical Center, Alabama, USA (J. Singh) and University of Otago, New Zealand (W. Taylor). J. Singh has received research grants from Takeda and Savient; and consultant fees from Savient, Takeda, Ardea, Regeneron, Allergan, URL pharmaceuticals and Novartis; and is a member of the executive of OMERACT, which receives arms-length funding from 36 companies; a member of the American College of Rheumatology Guidelines Subcommittee of the Quality of Care Committee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. N. Dalbeth has acted as a consultant for Ardea Biosciences, Metabolex, Novartis, and Takeda; her institution has received funding from Fonterra, and she is a named inventor on a patent related to milk products and gout. L. Simon has served on the Board of Directors for Savient Pharmaceuticals, and as a consultant for Takeda. J. Sundy has received research support from Savient Pharmaceuticals, Regeneron, Ardea Biosciences, Metabolex, Nuon Therapeutics, Pharmos; and consulting funds from Savient Pharmaceuticals, Regeneron, Novartis, Ardea Biosciences, Metabolex, Nuon Therapeutics, BioCryst, and Pharmos. V. Strand has received consultant fees from Metabolex, Novartis, and Savient. D. Khanna has received consultant fees from Ardea, Takeda, Novartis, and Savient; and has served on a Speaker Bureau for Savient. N. Schlesinger has received research grants from Novartis, worked on the Advisory Board for Novartis, Takeda, Savient, Enzyme Rx, URL Pharma; served on the Speaker Bureau for Novartis, Takeda, and Savient; and received consultant fees from Novartis and Takeda. K. Saag has received consultant fees from Ardea, Regeneron, and Takeda and served on the Data Safety Monitoring Board for BioCryst. R. Schumacher has received a grant from Takeda and is a consultant with Regeneron, Novartis, Ardea, Metabolex, Savient, BioCryst, Westward, and Pfizer. N. Edwards has received consultant fees from Takeda Pharmaceutical, Savient Pharmaceutical, Ardea Biosciences, Regeneron Pharmaceuticals, Metabolex Pharmaceuticals, and BioCryst Pharmaceuticals. Views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. J.A. Singh, MBBS, MPH, Associate Professor, Birmingham Veterans Affairs Medical Center and University of Alabama at Birmingham; W.J. Taylor, Associate Professor, PhD, FRACP, Department of Medicine, University of Otago; N. Dalbeth, MD, FRACP, Associate Professor, Faculty of Medical and Health Sciences, University of Auckland; L.S. Simon, MD, SDG LLC; J. Sundy, MD, PhD, Associate Professor, Duke University School of Medicine, and Duke-National University of Singapore Graduate Medical School; R. Grainger, MBChB, PhD, FRACP, Senior Lecturer, Department of Medicine, University of Otago Wellington; R. Alten, MD, Schlosspark-Klinik, Teaching Hospital of the Charité, University Medicine Berlin; L. March, MD, PhD, Professor, University of Sydney Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital; V. Strand, MD, FACP, FACR, Clinical Professor, Adjunct, Stanford University Division of Immunology and Rheumatology; G.A. Wells, MSc, PhD, University of Ottawa; D. Khanna, Associate Professor, MD, MS, University of Michigan Medical School; F. McQueen, Professor of Rheumatology, MBChB, MD, University of Auckland Department of Molecular Medicine and Pathology; N. Schlesinger, Professor of Medicine, Chief, Rutgers-Robert Wood Johnson Medical School; A. Boonen, MD, PhD, Maastricht University Medical Center Division of Rheumatology and Caphri Research Institute, University Maastricht; M. Boers, MD, PhD, VU University Medical Center; K. Saag, Professor, MD, MSc, University of Alabama at Birmingham; H.R. Schumacher Jr., University of Pennsylvania and Philadelphia Veterans Affairs Medical Center; N.L. Edwards, MD, Department of Rheumatology, University of Florida. Address correspondence to J. Singh, University of Alabama, Faculty Office Tower 805B, 510 20th St. S, Birmingham, Alabama 35294, USA; E-mail: Jasvinder.md@gmail.com
Maarten Boers
From Birmingham Veterans Affairs Medical Center and University of Alabama at Birmingham, Birmingham, Alabama, USA; Department of Medicine, University of Otago, Wellington; Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; SDG LLC, Cambridge, Massachusetts,; Duke University School of Medicine, Durham, North Carolina, USA, and Duke-National University of Singapore Graduate Medical School, Singapore; Schlosspark-Klinik Teaching Hospital of the Charité, University Medicine Berlin, Berlin, Germany; University of Sydney Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, Sydney, Australia; Stanford University Division of Immunology and Rheumatology, Portolo Valley, California, USA; University of Ottawa, London, Ontario, Canada; University of Michigan Medical School, Ann Arbor, Michigan, USA; University of Auckland, Department of Molecular Medicine and Pathology, Grafton, Auckland, New Zealand; Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA; Maastricht University Medical Center, Division of Rheumatology, and Caphri Research Institute, University Maastricht; VU University Medical Center, Amsterdam, the Netherlands; University of Pennsylvania and Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania; Department of Rheumatology, University of Florida, Gainsville, Florida, USA. Supported with the resources and the use of facilities at the Birmingham VA Medical Center, Alabama, USA (J. Singh) and University of Otago, New Zealand (W. Taylor). J. Singh has received research grants from Takeda and Savient; and consultant fees from Savient, Takeda, Ardea, Regeneron, Allergan, URL pharmaceuticals and Novartis; and is a member of the executive of OMERACT, which receives arms-length funding from 36 companies; a member of the American College of Rheumatology Guidelines Subcommittee of the Quality of Care Committee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. N. Dalbeth has acted as a consultant for Ardea Biosciences, Metabolex, Novartis, and Takeda; her institution has received funding from Fonterra, and she is a named inventor on a patent related to milk products and gout. L. Simon has served on the Board of Directors for Savient Pharmaceuticals, and as a consultant for Takeda. J. Sundy has received research support from Savient Pharmaceuticals, Regeneron, Ardea Biosciences, Metabolex, Nuon Therapeutics, Pharmos; and consulting funds from Savient Pharmaceuticals, Regeneron, Novartis, Ardea Biosciences, Metabolex, Nuon Therapeutics, BioCryst, and Pharmos. V. Strand has received consultant fees from Metabolex, Novartis, and Savient. D. Khanna has received consultant fees from Ardea, Takeda, Novartis, and Savient; and has served on a Speaker Bureau for Savient. N. Schlesinger has received research grants from Novartis, worked on the Advisory Board for Novartis, Takeda, Savient, Enzyme Rx, URL Pharma; served on the Speaker Bureau for Novartis, Takeda, and Savient; and received consultant fees from Novartis and Takeda. K. Saag has received consultant fees from Ardea, Regeneron, and Takeda and served on the Data Safety Monitoring Board for BioCryst. R. Schumacher has received a grant from Takeda and is a consultant with Regeneron, Novartis, Ardea, Metabolex, Savient, BioCryst, Westward, and Pfizer. N. Edwards has received consultant fees from Takeda Pharmaceutical, Savient Pharmaceutical, Ardea Biosciences, Regeneron Pharmaceuticals, Metabolex Pharmaceuticals, and BioCryst Pharmaceuticals. Views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. J.A. Singh, MBBS, MPH, Associate Professor, Birmingham Veterans Affairs Medical Center and University of Alabama at Birmingham; W.J. Taylor, Associate Professor, PhD, FRACP, Department of Medicine, University of Otago; N. Dalbeth, MD, FRACP, Associate Professor, Faculty of Medical and Health Sciences, University of Auckland; L.S. Simon, MD, SDG LLC; J. Sundy, MD, PhD, Associate Professor, Duke University School of Medicine, and Duke-National University of Singapore Graduate Medical School; R. Grainger, MBChB, PhD, FRACP, Senior Lecturer, Department of Medicine, University of Otago Wellington; R. Alten, MD, Schlosspark-Klinik, Teaching Hospital of the Charité, University Medicine Berlin; L. March, MD, PhD, Professor, University of Sydney Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital; V. Strand, MD, FACP, FACR, Clinical Professor, Adjunct, Stanford University Division of Immunology and Rheumatology; G.A. Wells, MSc, PhD, University of Ottawa; D. Khanna, Associate Professor, MD, MS, University of Michigan Medical School; F. McQueen, Professor of Rheumatology, MBChB, MD, University of Auckland Department of Molecular Medicine and Pathology; N. Schlesinger, Professor of Medicine, Chief, Rutgers-Robert Wood Johnson Medical School; A. Boonen, MD, PhD, Maastricht University Medical Center Division of Rheumatology and Caphri Research Institute, University Maastricht; M. Boers, MD, PhD, VU University Medical Center; K. Saag, Professor, MD, MSc, University of Alabama at Birmingham; H.R. Schumacher Jr., University of Pennsylvania and Philadelphia Veterans Affairs Medical Center; N.L. Edwards, MD, Department of Rheumatology, University of Florida. Address correspondence to J. Singh, University of Alabama, Faculty Office Tower 805B, 510 20th St. S, Birmingham, Alabama 35294, USA; E-mail: Jasvinder.md@gmail.com
Kenneth G. Saag
From Birmingham Veterans Affairs Medical Center and University of Alabama at Birmingham, Birmingham, Alabama, USA; Department of Medicine, University of Otago, Wellington; Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; SDG LLC, Cambridge, Massachusetts,; Duke University School of Medicine, Durham, North Carolina, USA, and Duke-National University of Singapore Graduate Medical School, Singapore; Schlosspark-Klinik Teaching Hospital of the Charité, University Medicine Berlin, Berlin, Germany; University of Sydney Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, Sydney, Australia; Stanford University Division of Immunology and Rheumatology, Portolo Valley, California, USA; University of Ottawa, London, Ontario, Canada; University of Michigan Medical School, Ann Arbor, Michigan, USA; University of Auckland, Department of Molecular Medicine and Pathology, Grafton, Auckland, New Zealand; Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA; Maastricht University Medical Center, Division of Rheumatology, and Caphri Research Institute, University Maastricht; VU University Medical Center, Amsterdam, the Netherlands; University of Pennsylvania and Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania; Department of Rheumatology, University of Florida, Gainsville, Florida, USA. Supported with the resources and the use of facilities at the Birmingham VA Medical Center, Alabama, USA (J. Singh) and University of Otago, New Zealand (W. Taylor). J. Singh has received research grants from Takeda and Savient; and consultant fees from Savient, Takeda, Ardea, Regeneron, Allergan, URL pharmaceuticals and Novartis; and is a member of the executive of OMERACT, which receives arms-length funding from 36 companies; a member of the American College of Rheumatology Guidelines Subcommittee of the Quality of Care Committee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. N. Dalbeth has acted as a consultant for Ardea Biosciences, Metabolex, Novartis, and Takeda; her institution has received funding from Fonterra, and she is a named inventor on a patent related to milk products and gout. L. Simon has served on the Board of Directors for Savient Pharmaceuticals, and as a consultant for Takeda. J. Sundy has received research support from Savient Pharmaceuticals, Regeneron, Ardea Biosciences, Metabolex, Nuon Therapeutics, Pharmos; and consulting funds from Savient Pharmaceuticals, Regeneron, Novartis, Ardea Biosciences, Metabolex, Nuon Therapeutics, BioCryst, and Pharmos. V. Strand has received consultant fees from Metabolex, Novartis, and Savient. D. Khanna has received consultant fees from Ardea, Takeda, Novartis, and Savient; and has served on a Speaker Bureau for Savient. N. Schlesinger has received research grants from Novartis, worked on the Advisory Board for Novartis, Takeda, Savient, Enzyme Rx, URL Pharma; served on the Speaker Bureau for Novartis, Takeda, and Savient; and received consultant fees from Novartis and Takeda. K. Saag has received consultant fees from Ardea, Regeneron, and Takeda and served on the Data Safety Monitoring Board for BioCryst. R. Schumacher has received a grant from Takeda and is a consultant with Regeneron, Novartis, Ardea, Metabolex, Savient, BioCryst, Westward, and Pfizer. N. Edwards has received consultant fees from Takeda Pharmaceutical, Savient Pharmaceutical, Ardea Biosciences, Regeneron Pharmaceuticals, Metabolex Pharmaceuticals, and BioCryst Pharmaceuticals. Views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. J.A. Singh, MBBS, MPH, Associate Professor, Birmingham Veterans Affairs Medical Center and University of Alabama at Birmingham; W.J. Taylor, Associate Professor, PhD, FRACP, Department of Medicine, University of Otago; N. Dalbeth, MD, FRACP, Associate Professor, Faculty of Medical and Health Sciences, University of Auckland; L.S. Simon, MD, SDG LLC; J. Sundy, MD, PhD, Associate Professor, Duke University School of Medicine, and Duke-National University of Singapore Graduate Medical School; R. Grainger, MBChB, PhD, FRACP, Senior Lecturer, Department of Medicine, University of Otago Wellington; R. Alten, MD, Schlosspark-Klinik, Teaching Hospital of the Charité, University Medicine Berlin; L. March, MD, PhD, Professor, University of Sydney Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital; V. Strand, MD, FACP, FACR, Clinical Professor, Adjunct, Stanford University Division of Immunology and Rheumatology; G.A. Wells, MSc, PhD, University of Ottawa; D. Khanna, Associate Professor, MD, MS, University of Michigan Medical School; F. McQueen, Professor of Rheumatology, MBChB, MD, University of Auckland Department of Molecular Medicine and Pathology; N. Schlesinger, Professor of Medicine, Chief, Rutgers-Robert Wood Johnson Medical School; A. Boonen, MD, PhD, Maastricht University Medical Center Division of Rheumatology and Caphri Research Institute, University Maastricht; M. Boers, MD, PhD, VU University Medical Center; K. Saag, Professor, MD, MSc, University of Alabama at Birmingham; H.R. Schumacher Jr., University of Pennsylvania and Philadelphia Veterans Affairs Medical Center; N.L. Edwards, MD, Department of Rheumatology, University of Florida. Address correspondence to J. Singh, University of Alabama, Faculty Office Tower 805B, 510 20th St. S, Birmingham, Alabama 35294, USA; E-mail: Jasvinder.md@gmail.com
H. Ralph Schumacher
From Birmingham Veterans Affairs Medical Center and University of Alabama at Birmingham, Birmingham, Alabama, USA; Department of Medicine, University of Otago, Wellington; Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; SDG LLC, Cambridge, Massachusetts,; Duke University School of Medicine, Durham, North Carolina, USA, and Duke-National University of Singapore Graduate Medical School, Singapore; Schlosspark-Klinik Teaching Hospital of the Charité, University Medicine Berlin, Berlin, Germany; University of Sydney Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, Sydney, Australia; Stanford University Division of Immunology and Rheumatology, Portolo Valley, California, USA; University of Ottawa, London, Ontario, Canada; University of Michigan Medical School, Ann Arbor, Michigan, USA; University of Auckland, Department of Molecular Medicine and Pathology, Grafton, Auckland, New Zealand; Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA; Maastricht University Medical Center, Division of Rheumatology, and Caphri Research Institute, University Maastricht; VU University Medical Center, Amsterdam, the Netherlands; University of Pennsylvania and Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania; Department of Rheumatology, University of Florida, Gainsville, Florida, USA. Supported with the resources and the use of facilities at the Birmingham VA Medical Center, Alabama, USA (J. Singh) and University of Otago, New Zealand (W. Taylor). J. Singh has received research grants from Takeda and Savient; and consultant fees from Savient, Takeda, Ardea, Regeneron, Allergan, URL pharmaceuticals and Novartis; and is a member of the executive of OMERACT, which receives arms-length funding from 36 companies; a member of the American College of Rheumatology Guidelines Subcommittee of the Quality of Care Committee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. N. Dalbeth has acted as a consultant for Ardea Biosciences, Metabolex, Novartis, and Takeda; her institution has received funding from Fonterra, and she is a named inventor on a patent related to milk products and gout. L. Simon has served on the Board of Directors for Savient Pharmaceuticals, and as a consultant for Takeda. J. Sundy has received research support from Savient Pharmaceuticals, Regeneron, Ardea Biosciences, Metabolex, Nuon Therapeutics, Pharmos; and consulting funds from Savient Pharmaceuticals, Regeneron, Novartis, Ardea Biosciences, Metabolex, Nuon Therapeutics, BioCryst, and Pharmos. V. Strand has received consultant fees from Metabolex, Novartis, and Savient. D. Khanna has received consultant fees from Ardea, Takeda, Novartis, and Savient; and has served on a Speaker Bureau for Savient. N. Schlesinger has received research grants from Novartis, worked on the Advisory Board for Novartis, Takeda, Savient, Enzyme Rx, URL Pharma; served on the Speaker Bureau for Novartis, Takeda, and Savient; and received consultant fees from Novartis and Takeda. K. Saag has received consultant fees from Ardea, Regeneron, and Takeda and served on the Data Safety Monitoring Board for BioCryst. R. Schumacher has received a grant from Takeda and is a consultant with Regeneron, Novartis, Ardea, Metabolex, Savient, BioCryst, Westward, and Pfizer. N. Edwards has received consultant fees from Takeda Pharmaceutical, Savient Pharmaceutical, Ardea Biosciences, Regeneron Pharmaceuticals, Metabolex Pharmaceuticals, and BioCryst Pharmaceuticals. Views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. J.A. Singh, MBBS, MPH, Associate Professor, Birmingham Veterans Affairs Medical Center and University of Alabama at Birmingham; W.J. Taylor, Associate Professor, PhD, FRACP, Department of Medicine, University of Otago; N. Dalbeth, MD, FRACP, Associate Professor, Faculty of Medical and Health Sciences, University of Auckland; L.S. Simon, MD, SDG LLC; J. Sundy, MD, PhD, Associate Professor, Duke University School of Medicine, and Duke-National University of Singapore Graduate Medical School; R. Grainger, MBChB, PhD, FRACP, Senior Lecturer, Department of Medicine, University of Otago Wellington; R. Alten, MD, Schlosspark-Klinik, Teaching Hospital of the Charité, University Medicine Berlin; L. March, MD, PhD, Professor, University of Sydney Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital; V. Strand, MD, FACP, FACR, Clinical Professor, Adjunct, Stanford University Division of Immunology and Rheumatology; G.A. Wells, MSc, PhD, University of Ottawa; D. Khanna, Associate Professor, MD, MS, University of Michigan Medical School; F. McQueen, Professor of Rheumatology, MBChB, MD, University of Auckland Department of Molecular Medicine and Pathology; N. Schlesinger, Professor of Medicine, Chief, Rutgers-Robert Wood Johnson Medical School; A. Boonen, MD, PhD, Maastricht University Medical Center Division of Rheumatology and Caphri Research Institute, University Maastricht; M. Boers, MD, PhD, VU University Medical Center; K. Saag, Professor, MD, MSc, University of Alabama at Birmingham; H.R. Schumacher Jr., University of Pennsylvania and Philadelphia Veterans Affairs Medical Center; N.L. Edwards, MD, Department of Rheumatology, University of Florida. Address correspondence to J. Singh, University of Alabama, Faculty Office Tower 805B, 510 20th St. S, Birmingham, Alabama 35294, USA; E-mail: Jasvinder.md@gmail.com
N. Lawrence Edwards
From Birmingham Veterans Affairs Medical Center and University of Alabama at Birmingham, Birmingham, Alabama, USA; Department of Medicine, University of Otago, Wellington; Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; SDG LLC, Cambridge, Massachusetts,; Duke University School of Medicine, Durham, North Carolina, USA, and Duke-National University of Singapore Graduate Medical School, Singapore; Schlosspark-Klinik Teaching Hospital of the Charité, University Medicine Berlin, Berlin, Germany; University of Sydney Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, Sydney, Australia; Stanford University Division of Immunology and Rheumatology, Portolo Valley, California, USA; University of Ottawa, London, Ontario, Canada; University of Michigan Medical School, Ann Arbor, Michigan, USA; University of Auckland, Department of Molecular Medicine and Pathology, Grafton, Auckland, New Zealand; Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA; Maastricht University Medical Center, Division of Rheumatology, and Caphri Research Institute, University Maastricht; VU University Medical Center, Amsterdam, the Netherlands; University of Pennsylvania and Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania; Department of Rheumatology, University of Florida, Gainsville, Florida, USA. Supported with the resources and the use of facilities at the Birmingham VA Medical Center, Alabama, USA (J. Singh) and University of Otago, New Zealand (W. Taylor). J. Singh has received research grants from Takeda and Savient; and consultant fees from Savient, Takeda, Ardea, Regeneron, Allergan, URL pharmaceuticals and Novartis; and is a member of the executive of OMERACT, which receives arms-length funding from 36 companies; a member of the American College of Rheumatology Guidelines Subcommittee of the Quality of Care Committee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. N. Dalbeth has acted as a consultant for Ardea Biosciences, Metabolex, Novartis, and Takeda; her institution has received funding from Fonterra, and she is a named inventor on a patent related to milk products and gout. L. Simon has served on the Board of Directors for Savient Pharmaceuticals, and as a consultant for Takeda. J. Sundy has received research support from Savient Pharmaceuticals, Regeneron, Ardea Biosciences, Metabolex, Nuon Therapeutics, Pharmos; and consulting funds from Savient Pharmaceuticals, Regeneron, Novartis, Ardea Biosciences, Metabolex, Nuon Therapeutics, BioCryst, and Pharmos. V. Strand has received consultant fees from Metabolex, Novartis, and Savient. D. Khanna has received consultant fees from Ardea, Takeda, Novartis, and Savient; and has served on a Speaker Bureau for Savient. N. Schlesinger has received research grants from Novartis, worked on the Advisory Board for Novartis, Takeda, Savient, Enzyme Rx, URL Pharma; served on the Speaker Bureau for Novartis, Takeda, and Savient; and received consultant fees from Novartis and Takeda. K. Saag has received consultant fees from Ardea, Regeneron, and Takeda and served on the Data Safety Monitoring Board for BioCryst. R. Schumacher has received a grant from Takeda and is a consultant with Regeneron, Novartis, Ardea, Metabolex, Savient, BioCryst, Westward, and Pfizer. N. Edwards has received consultant fees from Takeda Pharmaceutical, Savient Pharmaceutical, Ardea Biosciences, Regeneron Pharmaceuticals, Metabolex Pharmaceuticals, and BioCryst Pharmaceuticals. Views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. J.A. Singh, MBBS, MPH, Associate Professor, Birmingham Veterans Affairs Medical Center and University of Alabama at Birmingham; W.J. Taylor, Associate Professor, PhD, FRACP, Department of Medicine, University of Otago; N. Dalbeth, MD, FRACP, Associate Professor, Faculty of Medical and Health Sciences, University of Auckland; L.S. Simon, MD, SDG LLC; J. Sundy, MD, PhD, Associate Professor, Duke University School of Medicine, and Duke-National University of Singapore Graduate Medical School; R. Grainger, MBChB, PhD, FRACP, Senior Lecturer, Department of Medicine, University of Otago Wellington; R. Alten, MD, Schlosspark-Klinik, Teaching Hospital of the Charité, University Medicine Berlin; L. March, MD, PhD, Professor, University of Sydney Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital; V. Strand, MD, FACP, FACR, Clinical Professor, Adjunct, Stanford University Division of Immunology and Rheumatology; G.A. Wells, MSc, PhD, University of Ottawa; D. Khanna, Associate Professor, MD, MS, University of Michigan Medical School; F. McQueen, Professor of Rheumatology, MBChB, MD, University of Auckland Department of Molecular Medicine and Pathology; N. Schlesinger, Professor of Medicine, Chief, Rutgers-Robert Wood Johnson Medical School; A. Boonen, MD, PhD, Maastricht University Medical Center Division of Rheumatology and Caphri Research Institute, University Maastricht; M. Boers, MD, PhD, VU University Medical Center; K. Saag, Professor, MD, MSc, University of Alabama at Birmingham; H.R. Schumacher Jr., University of Pennsylvania and Philadelphia Veterans Affairs Medical Center; N.L. Edwards, MD, Department of Rheumatology, University of Florida. Address correspondence to J. Singh, University of Alabama, Faculty Office Tower 805B, 510 20th St. S, Birmingham, Alabama 35294, USA; E-mail: Jasvinder.md@gmail.com
Article Information
jrheum.131246
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online December 15, 2013.
Article Versions
- You are currently viewing a Latest version of this article (December 15, 2013 - 04:00).
- View the most recent version of this article
Copyright & Usage
© 2013 The Journal of Rheumatology
Author Information
- Jasvinder A. Singh,
- William J. Taylor,
- Nicola Dalbeth,
- Lee S. Simon,
- John Sundy,
- Rebecca Grainger,
- Rieke Alten,
- Lyn March,
- Vibeke Strand,
- George Wells,
- Dinesh Khanna,
- Fiona McQueen,
- Naomi Schlesinger,
- Annelies Boonen,
- Maarten Boers,
- Kenneth G. Saag,
- H. Ralph Schumacher and
- N. Lawrence Edwards
- From Birmingham Veterans Affairs Medical Center and University of Alabama at Birmingham, Birmingham, Alabama, USA; Department of Medicine, University of Otago, Wellington; Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; SDG LLC, Cambridge, Massachusetts,; Duke University School of Medicine, Durham, North Carolina, USA, and Duke-National University of Singapore Graduate Medical School, Singapore; Schlosspark-Klinik Teaching Hospital of the Charité, University Medicine Berlin, Berlin, Germany; University of Sydney Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, Sydney, Australia; Stanford University Division of Immunology and Rheumatology, Portolo Valley, California, USA; University of Ottawa, London, Ontario, Canada; University of Michigan Medical School, Ann Arbor, Michigan, USA; University of Auckland, Department of Molecular Medicine and Pathology, Grafton, Auckland, New Zealand; Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA; Maastricht University Medical Center, Division of Rheumatology, and Caphri Research Institute, University Maastricht; VU University Medical Center, Amsterdam, the Netherlands; University of Pennsylvania and Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania; Department of Rheumatology, University of Florida, Gainsville, Florida, USA.
Supported with the resources and the use of facilities at the Birmingham VA Medical Center, Alabama, USA (J. Singh) and University of Otago, New Zealand (W. Taylor). J. Singh has received research grants from Takeda and Savient; and consultant fees from Savient, Takeda, Ardea, Regeneron, Allergan, URL pharmaceuticals and Novartis; and is a member of the executive of OMERACT, which receives arms-length funding from 36 companies; a member of the American College of Rheumatology Guidelines Subcommittee of the Quality of Care Committee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. N. Dalbeth has acted as a consultant for Ardea Biosciences, Metabolex, Novartis, and Takeda; her institution has received funding from Fonterra, and she is a named inventor on a patent related to milk products and gout. L. Simon has served on the Board of Directors for Savient Pharmaceuticals, and as a consultant for Takeda. J. Sundy has received research support from Savient Pharmaceuticals, Regeneron, Ardea Biosciences, Metabolex, Nuon Therapeutics, Pharmos; and consulting funds from Savient Pharmaceuticals, Regeneron, Novartis, Ardea Biosciences, Metabolex, Nuon Therapeutics, BioCryst, and Pharmos. V. Strand has received consultant fees from Metabolex, Novartis, and Savient. D. Khanna has received consultant fees from Ardea, Takeda, Novartis, and Savient; and has served on a Speaker Bureau for Savient. N. Schlesinger has received research grants from Novartis, worked on the Advisory Board for Novartis, Takeda, Savient, Enzyme Rx, URL Pharma; served on the Speaker Bureau for Novartis, Takeda, and Savient; and received consultant fees from Novartis and Takeda. K. Saag has received consultant fees from Ardea, Regeneron, and Takeda and served on the Data Safety Monitoring Board for BioCryst. R. Schumacher has received a grant from Takeda and is a consultant with Regeneron, Novartis, Ardea, Metabolex, Savient, BioCryst, Westward, and Pfizer. N. Edwards has received consultant fees from Takeda Pharmaceutical, Savient Pharmaceutical, Ardea Biosciences, Regeneron Pharmaceuticals, Metabolex Pharmaceuticals, and BioCryst Pharmaceuticals. Views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government.
J.A. Singh, MBBS, MPH, Associate Professor, Birmingham Veterans Affairs Medical Center and University of Alabama at Birmingham; W.J. Taylor, Associate Professor, PhD, FRACP, Department of Medicine, University of Otago; N. Dalbeth, MD, FRACP, Associate Professor, Faculty of Medical and Health Sciences, University of Auckland; L.S. Simon, MD, SDG LLC; J. Sundy, MD, PhD, Associate Professor, Duke University School of Medicine, and Duke-National University of Singapore Graduate Medical School; R. Grainger, MBChB, PhD, FRACP, Senior Lecturer, Department of Medicine, University of Otago Wellington; R. Alten, MD, Schlosspark-Klinik, Teaching Hospital of the Charité, University Medicine Berlin; L. March, MD, PhD, Professor, University of Sydney Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital; V. Strand, MD, FACP, FACR, Clinical Professor, Adjunct, Stanford University Division of Immunology and Rheumatology; G.A. Wells, MSc, PhD, University of Ottawa; D. Khanna, Associate Professor, MD, MS, University of Michigan Medical School; F. McQueen, Professor of Rheumatology, MBChB, MD, University of Auckland Department of Molecular Medicine and Pathology; N. Schlesinger, Professor of Medicine, Chief, Rutgers-Robert Wood Johnson Medical School; A. Boonen, MD, PhD, Maastricht University Medical Center Division of Rheumatology and Caphri Research Institute, University Maastricht; M. Boers, MD, PhD, VU University Medical Center; K. Saag, Professor, MD, MSc, University of Alabama at Birmingham; H.R. Schumacher Jr., University of Pennsylvania and Philadelphia Veterans Affairs Medical Center; N.L. Edwards, MD, Department of Rheumatology, University of Florida.
Address correspondence to J. Singh, University of Alabama, Faculty Office Tower 805B, 510 20th St. S, Birmingham, Alabama 35294, USA; E-mail: Jasvinder.md@gmail.com
Article usage
Statistics from Altmetric.com
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
OMERACT Endorsement of Measures of Outcome for Studies of Acute Gout
Jasvinder A. Singh, William J. Taylor, Nicola Dalbeth, Lee S. Simon, John Sundy, Rebecca Grainger, Rieke Alten, Lyn March, Vibeke Strand, George Wells, Dinesh Khanna, Fiona McQueen, Naomi Schlesinger, Annelies Boonen, Maarten Boers, Kenneth G. Saag, H. Ralph Schumacher, N. Lawrence Edwards
The Journal of Rheumatology Dec 2013, jrheum.131246; DOI: 10.3899/jrheum.131246
OMERACT Endorsement of Measures of Outcome for Studies of Acute Gout
Jasvinder A. Singh, William J. Taylor, Nicola Dalbeth, Lee S. Simon, John Sundy, Rebecca Grainger, Rieke Alten, Lyn March, Vibeke Strand, George Wells, Dinesh Khanna, Fiona McQueen, Naomi Schlesinger, Annelies Boonen, Maarten Boers, Kenneth G. Saag, H. Ralph Schumacher, N. Lawrence Edwards
The Journal of Rheumatology Dec 2013, jrheum.131246; DOI: 10.3899/jrheum.131246